Fluorescence diagnosis and photodynamic therapy in urology;Fluoreszenzdiagnostik und Photodynamische Therapie in der Urologie

Aktuelle Urologie

Volumn 38, Issue 6, 2007, Pages 455-464

  Stepp, H ^a   Waldelich, R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Aminolevulinic acid; Bladder cancer; Cystoscopy; Fluorescence; Hexaminolevulinate; Photodynamic therapy; Photosensitizers; Phototoxicity

Indexed keywords

5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLADDER TUMOR; CARCINOMA IN SITU; COMPARATIVE STUDY; CONTACT DERMATITIS; CYSTOSCOPY; FLUORESCENCE; FOLLOW UP; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOCHEMOTHERAPY; PILOT STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TIME; TUMOR RECURRENCE;

AMINOLEVULINIC ACID; CARCINOMA IN SITU; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYSTOSCOPY; DERMATITIS, PHOTOTOXIC; FLUORESCENCE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 36749016756     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-980149     Document Type: Article

References (79)

1. Haukaas S, Daehlin L, Maartmann-Moe H, Ulvik NM. The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience. BJU Int 1999; 83: 957-963
2. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573- 1583
3. Witjes JA. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 2004; 45: 142-146
4. Jichlinski P. New diagnostic strategies in the detection and staging of bladder cancer. Curr Opin Urol 2003; 13: 351-355
5. Allison RR, Bagnato VS, Cuenca R, Downie GH, Sibata CH. The future of photodynamic therapy in oncology. Future Oncol 2006; 2: 53-71
6. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005; 4: 283 - 293
7. Pottier R, Krammer B, Stepp H, Baumgartner R (editors). Photodynamic Therapy with ALA, A Clinical Handbook. Cambridge: RSC Publishing, 2006
8. Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N. 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. Photochem Photobiol 2006; 82: 994-1015
9. Batlle AM. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B 1993; 20: 5-22
10. Marti A, Jichlinski P, Lange N et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003; 170: 428-432
11. Tappeiner HV. Die photodynamische Erscheinung. In: Asher L, Spiro K (eds). Ergebnisse der Physiologie Wiesbaden: Verlag von J. F. Bergmann, 1909: 698-741
12. Jocham D, Staehler G, Baumgartner R, Unsold E. [Integral photodynamic therapy of multifocal bladder cancer. Initial clinical experiences]. Urologe A 1985; 24: 316-319
13. Tappeiner HV, Jesionek A. Therapeutische Versuche mit fluoreszierenden Stoffen. Muench Med Wochenschr 1903; 47: 2042-2044
14. Dougherty TJ. Photosensitization of malignant tumors. Semin Surg Oncol 1986; 2: 24-37
15. Nseyo UO, Dougherty TJ, Boyle DC et al. Whole bladder photodynamic therapy for transitional cell carcinoma of bladder. Urology 1985; 26: 274-280
16. Loidl W, Schmidbauer J, Susani M, Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 2005; 47: 323-326
17. Witjes JA, Moonen PM, Heijden AG van der. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 2005; 47: 319-322
18. Jichlinski P, Guillou L Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J Urol 2003 ; 170: 226 - 229
19. Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 862-866
20. Hungerhuber E, Stepp H, Kriegmair M et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007; 69: 260-264
21. Fradet Y, Grossman HB, Gomella L et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 68 - 73
22. Grossman HB, Gomella L, Fradet Y et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178: 62-67
23. Zaak D, Kriegmair M, Stepp H et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001; 57: 690-694
24. Zaak D, Hungerhuber E, Schneede P et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002; 95: 1234-1238
25. Hendricksen K, Moonen PM, der Heijden AG, Witjes JA. False-positive lesions detected by fluorescence cystoscopy: any association with p53 and p16 expression? World J Urol 2006; 24: 597-601
26. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology 1999; 53: 77-81
27. Grimbergen MC, Swol CF van, Jonges TG, Boon TA, Moorselaar RJ van. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003; 44: 51 - 56
28. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999; 154: 721-727
29. Kriegmair M, Zaak D, Rothenberger KH et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002; 168: 475-478
30. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001; 165: 1121 -1123
31. Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69: 675- 679
32. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168: 67 - 71
33. Alken P, Siegsmund M, Gromoll-Bergmann K, Daffner P, Fenner W, Spelz J. A randomized controlled multicentre trial to compare the effects of transurethral resection of bladder carcinomas under 5-ALA induced fluorescence light to conventional white light. Poster presented at Annual EAU congress, March 21-24, 2007 Berlin, Germany, 2007
34. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96: 798-802
35. Daniltchenko Dl, Riedl CR, Sachs MD et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005; 174: 2129-2133, discussion
36. Penkoff H, Steiner H, Dajc-Sommerer E et al. Transurethral Detection and Resection of Bladder Carcinomas Under White or 5-ALA Induced Fluorescence Light: Results of the First Double-Blind Placebo-Controlled Clinical Trial, Abstract 1085 presented at Annual AUA congress, May 19 - 24, 2007. Anaheim, CA, 2007
37. Rick K, Sroka R, Stepp H et al. Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood, Journal of Photochemistry and Photobiology B: Biology 1997; 40: 313-319
38. Klem B, Lappin G, Nicholson S et al. Determination of the bioavailability of [ 14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J Clin Pharmacol 2006; 46: 456-460
39. Colapaoli L, Thorsen J, Nopp A, Guttormsen AB. A case of anaphylactic shock possibly caused by intravesical Hexvix. Acta Anaesthesiol Scand 2006; 50: 1165-1167
40. Avritscher EB, Cooksley CD, Grossman HB et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68: 549-553
41. Koenig F, Knittel J, Stepp H. Diagnosing cancer in vivo. Science 2001; 292: 1401-1413
42. Jichlinski P, Leisinger HJ. Photodynamic therapy in superficial bladder cancer: past, present and future. Urol Res 2001; 29: 396-405
43. Beyer W. Systems for light application and dosimetry in photodynamic therapy. J Photochem Photobiol B 1996; 36: 153-156
44. Staveren HJ van, Keijzer M, Keesmaat T et al. Integrating sphere effect in whole-bladder wall photodynamic therapy: III. Fluence multiplication, optical penetration and light distribution with an eccentric source for human bladder optical properties. Phys Med Biol 1996; 41: 579-590
45. Beyer W, Waidelich R, Knuechel R, Stepp H, Baumgartner R, Hofstetter A. Technical concepts for white light photodynamic therapy of bladder cancer. Medical Laser Application 2002; 17: 37-40
46. Waidelich R, Beyer W, Knuechel R et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003; 61: 332-337
47. Jichlinski P. Photodynamic applications in superficial bladder cancer: facts and hopesl J Environ Pathol Toxicol Oncol 2006; 25: 441-451
48. Waidelich R, Stepp H, BaumgartnerR, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001; 165: 1904-1907
49. Bader M, Zaak D, Stief C et al. Photodynamic Therapy of bladder cancer - a phase I study using hexyl-aminolevulinate. Poster presented at Annual EAU congress, March 21-24, 2007. Berlin, Germany, 2007
50. Shackley DC, Briggs C, Gilhooley A et al. Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU Int 2002; 89: 665-670
51. Tauber S, Stepp H, Meier R, Bone A, Hofstetter A, Stief C. Integral spectrophotometry analysis of 5-aminolaevulinic acid-induced fluorescence cytology of the urinary bladder. BJU Int 2006; 97: 992 - 996
52. Pytel A, Schmeller N. New aspect of photodynamic diagnosis of bladder tumors: fluorescence cytology. Urology 2002; 59: 216-219
53. Waidelich R, Hofstetter A, Stepp H, Baumgartner R, Weninger E, Kriegmair M. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. J Urol 1998; 159: 401-404
54. Schneede P, Munch P, Wagner S, Meyer T, Stockfleth E, Hofstetter A. Fluorescence urethroscopy following instillation of 5-aminolevulinic acid: a new procedure for detecting clinical and subclinical HPV lesions of the urethra. J Eur Acad Dermatol Venereol 2001; 15: 121 - 125
55. Zaak D, Hofstetter A, Frimberger D, Schneede P. Recurrence of condylomata acuminata of the urethra after conventional and fluorescencecontrolled Nd:YAG laser treatment. Urology 2003; 61: 1011 - 1015
56. Wang XL Wang HW, Wang HS, Xu SZ, Liao KH, Hillemanns P. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. BrJ Dermatol 2004; 151: 880-885
57. Popken G, Wetterauer U, Schultze-Seemann W. Kidney-preserving tumor resection in renal cell carcinoma with photodynamic detection by 5-aminolaevulinic acid: preclinical and preliminary clinical results. BJU Int 1999; 83: 578-582
58. Frimberger D, Schneede P, Hungerhuber E et al. Autofluorescence and 5-aminolevulinic acid induced fluorescence diagnosis of penile carcinoma - new techniques to monitor Nd:YAG laser therapy. Urol Res 2002; 30: 295-300
59. Pinthus JH, Bogaards A, Weersink R, Wilson BC, TrachtenbergJ. Photodynamic therapy for urological malignancies: past to current approaches. J Urol 2006; 175: 1201-1207
60. Zaak D, Sroka R, Höppner M et al. Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer - Preliminary results. Medical Laser Application 2003; 18: 91-95
61. Zaak D, Sroka R, Stocker S et al. Photodynamic therapy of prostate cancer by means of 5-aminolevulinic acid-induced protoporphyrin IX - In vivo experiments on the Dunning rat tumor model. Urologia Internationalis 2004; 72: 196-202
62. Moore CM, Nathan TR, Lees WR et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med 2006; 38: 356-363
63. Weersink RA Bogaards A, Gertner M et al. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B 2005; 79: 211-222
64. Verigos K, Stripp DC, Mick R et al. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 2006; 25: 373-387
65. Zhou X, Pogue BW, Chen B et al. Pretreatment photosensitizer dosimetry reduces variation in tumor response. Int J Radiat Oncol Biol Phys 2006; 64: 1211-1220
66. Jankun J, Keck RW, Skrzypczak-Jankun E, Lilge L, Selman SH. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. BJU Int 2005; 95: 1237-1244
67. Yu G, Durduran T, Zhou C et al. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. Photochem Photobiol 2006; 82: 1279-1284
68. Thompson MS, Johansson A, Johansson T et al. Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements. Appl Opt 2005; 44: 4023-4031
69. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 135-138
70. Lopatkin NA, Kamalov AA, Kudriavtsev I, Tokarev FV. [Fluorescent diagnostics of urinary bladder cancer]. Urologiia 2000; 4: 3-6
71. Koenig F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999; 83: 129-135
72. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. J Endourol 1999; 13: 755-759
73. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 1999; 13: 117-121
74. Kriegmair M, Baumgartner R, Knüchel R, Stepp H, Hofstaedter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155: 105-110
75. Sim HG, Lau WK, Olivo M, Tan PH, Cheng CW. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? BJU Int 2005; 95: 1215 - 1218
76. D'Hallewin MA, Bezdetnaya L Guillemin F. Fluorescence detection of bladder cancer: a review. Eur Urol 2002; 42: 417-425
77. D'Hallewin MA, De Witte PA, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin, J Urol 2000; 164: 349-351
78. Kriegmair M, Baumgartner R, Lumper W et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 1996; 77: 667-671
79. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003; 61: 338-341